| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Oseltamivir | 4 | 2021 | 583 | 0.90 | Why? |
| Thiepins | 1 | 2018 | 10 | 0.77 | Why? |
| Influenza, Human | 12 | 2021 | 10779 | 0.74 | Why? |
| Triazines | 3 | 2021 | 246 | 0.71 | Why? |
| Rhinovirus | 10 | 2006 | 979 | 0.68 | Why? |
| Oxazines | 1 | 2018 | 279 | 0.65 | Why? |
| Respiratory Tract Infections | 10 | 2017 | 6817 | 0.58 | Why? |
| Antiviral Agents | 20 | 2021 | 41703 | 0.54 | Why? |
| Interferon beta-1b | 4 | 2020 | 274 | 0.51 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.48 | Why? |
| Dibenzothiepins | 3 | 2021 | 39 | 0.46 | Why? |
| Common Cold | 5 | 2002 | 645 | 0.45 | Why? |
| Picornaviridae Infections | 5 | 2003 | 544 | 0.41 | Why? |
| Ebolavirus | 1 | 2017 | 834 | 0.40 | Why? |
| Hemorrhagic Fever, Ebola | 2 | 2017 | 1475 | 0.37 | Why? |
| Macrolides | 2 | 2020 | 369 | 0.30 | Why? |
| Virus Diseases | 4 | 2014 | 3779 | 0.30 | Why? |
| Lopinavir | 4 | 2020 | 4308 | 0.28 | Why? |
| Respiratory Syncytial Virus Infections | 4 | 2014 | 1234 | 0.28 | Why? |
| Ritonavir | 4 | 2020 | 4212 | 0.27 | Why? |
| Critical Care | 4 | 2021 | 14081 | 0.27 | Why? |
| Morpholines | 3 | 2021 | 351 | 0.25 | Why? |
| Severe Acute Respiratory Syndrome | 3 | 2020 | 12361 | 0.24 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 8 | 2020 | 8843 | 0.24 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.23 | Why? |
| Double-Blind Method | 7 | 2020 | 5988 | 0.21 | Why? |
| Intention to Treat Analysis | 2 | 2020 | 673 | 0.20 | Why? |
| Viruses | 1 | 2013 | 2238 | 0.20 | Why? |
| Neuraminidase | 2 | 2021 | 289 | 0.19 | Why? |
| Pyridones | 3 | 2021 | 738 | 0.19 | Why? |
| Saudi Arabia | 9 | 2020 | 4423 | 0.19 | Why? |
| Coronavirus Infections | 25 | 2020 | 253789 | 0.19 | Why? |
| Otitis Media with Effusion | 1 | 1998 | 39 | 0.18 | Why? |
| Endonucleases | 1 | 2018 | 68 | 0.18 | Why? |
| Otitis Media | 2 | 2002 | 106 | 0.18 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.18 | Why? |
| Critical Illness | 8 | 2020 | 17281 | 0.18 | Why? |
| Coronavirus | 7 | 2020 | 18339 | 0.17 | Why? |
| Ebola Vaccines | 1 | 2017 | 126 | 0.16 | Why? |
| Intensive Care Units | 8 | 2021 | 29594 | 0.16 | Why? |
| Noninvasive Ventilation | 2 | 2020 | 2329 | 0.15 | Why? |
| Respiration, Artificial | 3 | 2020 | 22116 | 0.15 | Why? |
| Sialic Acids | 1 | 1997 | 218 | 0.15 | Why? |
| Influenza A Virus, H5N1 Subtype | 2 | 2012 | 492 | 0.15 | Why? |
| Ribavirin | 2 | 2020 | 1182 | 0.14 | Why? |
| Respiratory Syncytial Viruses | 1 | 1998 | 612 | 0.14 | Why? |
| Therapies, Investigational | 1 | 2017 | 235 | 0.14 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.14 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.14 | Why? |
| Coronaviridae Infections | 1 | 1998 | 442 | 0.13 | Why? |
| Respiratory Syncytial Virus, Human | 3 | 2002 | 846 | 0.13 | Why? |
| Middle East | 2 | 2017 | 1418 | 0.12 | Why? |
| Post-Exposure Prophylaxis | 1 | 2017 | 472 | 0.12 | Why? |
| Drug Resistance, Fungal | 1 | 2014 | 191 | 0.12 | Why? |
| Drug Resistance, Viral | 2 | 2021 | 1083 | 0.12 | Why? |
| Kaplan-Meier Estimate | 2 | 2020 | 4260 | 0.12 | Why? |
| Community-Acquired Infections | 3 | 2020 | 2328 | 0.12 | Why? |
| Adrenal Cortex Hormones | 2 | 2021 | 6537 | 0.12 | Why? |
| Pneumonia | 3 | 2020 | 5652 | 0.11 | Why? |
| Polymerase Chain Reaction | 5 | 1999 | 6740 | 0.11 | Why? |
| Humans | 52 | 2021 | 930598 | 0.11 | Why? |
| Influenza B virus | 1 | 1997 | 815 | 0.11 | Why? |
| Enzyme Inhibitors | 2 | 2021 | 1881 | 0.11 | Why? |
| Immunotherapy | 2 | 2016 | 2421 | 0.10 | Why? |
| Ear, Middle | 2 | 2002 | 61 | 0.10 | Why? |
| SARS Virus | 2 | 2012 | 13021 | 0.10 | Why? |
| Evidence-Based Medicine | 2 | 2021 | 3228 | 0.10 | Why? |
| Zanamivir | 2 | 2021 | 63 | 0.10 | Why? |
| Sinusitis | 1 | 1997 | 649 | 0.10 | Why? |
| Communicable Diseases, Emerging | 2 | 2014 | 2523 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.10 | Why? |
| Cell Adhesion Molecules | 1 | 1992 | 472 | 0.09 | Why? |
| Treatment Failure | 3 | 2020 | 2106 | 0.09 | Why? |
| Rimantadine | 1 | 1987 | 13 | 0.09 | Why? |
| Bacterial Infections | 3 | 2014 | 2229 | 0.09 | Why? |
| Multicenter Studies as Topic | 3 | 2020 | 2437 | 0.09 | Why? |
| Virus Replication | 6 | 2021 | 14331 | 0.09 | Why? |
| Mycoses | 1 | 2014 | 589 | 0.09 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2012 | 572 | 0.08 | Why? |
| Influenza A virus | 2 | 1997 | 2234 | 0.08 | Why? |
| Adamantane | 1 | 1987 | 68 | 0.08 | Why? |
| Infant | 7 | 2020 | 30274 | 0.08 | Why? |
| Seasons | 3 | 2002 | 4071 | 0.08 | Why? |
| Amantadine | 1 | 1987 | 79 | 0.08 | Why? |
| Plasma | 1 | 2016 | 1809 | 0.08 | Why? |
| Molecular Epidemiology | 1 | 2012 | 1638 | 0.08 | Why? |
| Practice Guidelines as Topic | 2 | 2021 | 15421 | 0.08 | Why? |
| Drug Therapy, Combination | 4 | 2020 | 7268 | 0.08 | Why? |
| Infusions, Intravenous | 2 | 2020 | 1224 | 0.08 | Why? |
| Drug Combinations | 3 | 2020 | 3852 | 0.07 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.07 | Why? |
| Drug Resistance, Bacterial | 1 | 2014 | 1414 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.07 | Why? |
| Occupational Diseases | 1 | 2018 | 2787 | 0.06 | Why? |
| Metapneumovirus | 1 | 2006 | 465 | 0.06 | Why? |
| Male | 21 | 2020 | 367725 | 0.06 | Why? |
| Viral Load | 3 | 2020 | 15850 | 0.06 | Why? |
| Interferon-beta | 1 | 1989 | 979 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Female | 21 | 2020 | 380317 | 0.06 | Why? |
| Disease Management | 1 | 2021 | 6841 | 0.06 | Why? |
| Middle Aged | 16 | 2020 | 270681 | 0.06 | Why? |
| Picornaviridae | 1 | 1982 | 123 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.06 | Why? |
| RNA Viruses | 1 | 1989 | 824 | 0.06 | Why? |
| Treatment Outcome | 8 | 2020 | 51732 | 0.06 | Why? |
| Adult | 12 | 2020 | 244371 | 0.06 | Why? |
| Child | 7 | 2020 | 70012 | 0.06 | Why? |
| Shock | 2 | 2020 | 1868 | 0.05 | Why? |
| Interferon-alpha | 1 | 1989 | 1442 | 0.05 | Why? |
| Time Factors | 7 | 2020 | 31397 | 0.05 | Why? |
| Equivalence Trials as Topic | 1 | 2020 | 242 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.05 | Why? |
| Karnofsky Performance Status | 1 | 2018 | 88 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.05 | Why? |
| Child, Preschool | 7 | 2020 | 36283 | 0.05 | Why? |
| Ribonucleases | 1 | 1999 | 89 | 0.05 | Why? |
| Middle Ear Ventilation | 1 | 1998 | 40 | 0.05 | Why? |
| National Institutes of Health (U.S.) | 1 | 2021 | 443 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Injections, Subcutaneous | 1 | 2020 | 647 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2014 | 2941 | 0.04 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2020 | 265 | 0.04 | Why? |
| Pyrans | 1 | 1997 | 56 | 0.04 | Why? |
| Immunocompromised Host | 1 | 2014 | 5150 | 0.04 | Why? |
| Nitriles | 1 | 1982 | 1053 | 0.04 | Why? |
| Virginia | 1 | 1997 | 228 | 0.04 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 2984 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2020 | 1008 | 0.04 | Why? |
| Knowledge | 1 | 2021 | 452 | 0.04 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.04 | Why? |
| Sneezing | 1 | 1997 | 173 | 0.04 | Why? |
| Aged | 11 | 2020 | 215776 | 0.04 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.04 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.04 | Why? |
| Respiratory Sounds | 1 | 1999 | 294 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.04 | Why? |
| Cells, Cultured | 3 | 1998 | 5835 | 0.04 | Why? |
| Interferon Type I | 1 | 1989 | 2789 | 0.04 | Why? |
| Immunoglobulin E | 1 | 1999 | 557 | 0.04 | Why? |
| Leukopenia | 1 | 2017 | 280 | 0.04 | Why? |
| Biomedical Research | 1 | 2016 | 5270 | 0.04 | Why? |
| Data Interpretation, Statistical | 1 | 2020 | 657 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Adolescent | 5 | 2018 | 86841 | 0.03 | Why? |
| HeLa Cells | 2 | 1992 | 1303 | 0.03 | Why? |
| Peptide Hydrolases | 1 | 2021 | 1269 | 0.03 | Why? |
| Ventilation | 1 | 2021 | 1145 | 0.03 | Why? |
| Vasoconstrictor Agents | 1 | 2017 | 714 | 0.03 | Why? |
| Time-to-Treatment | 2 | 2020 | 5883 | 0.03 | Why? |
| Pharyngitis | 1 | 1997 | 687 | 0.03 | Why? |
| Global Health | 2 | 2020 | 13911 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Guanidines | 1 | 1997 | 499 | 0.03 | Why? |
| Administration, Intranasal | 1 | 1997 | 1132 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Internationality | 1 | 2006 | 3297 | 0.03 | Why? |
| Hemodynamics | 1 | 2021 | 1562 | 0.03 | Why? |
| Antibodies, Monoclonal | 1 | 2012 | 8041 | 0.03 | Why? |
| Eosinophils | 1 | 1999 | 848 | 0.03 | Why? |
| Drug Therapy | 1 | 2014 | 280 | 0.03 | Why? |
| Viral Plaque Assay | 1 | 2013 | 381 | 0.03 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.03 | Why? |
| Mycophenolic Acid | 1 | 2013 | 383 | 0.03 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 1992 | 189 | 0.03 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.03 | Why? |
| Virulence | 1 | 1998 | 2172 | 0.03 | Why? |
| Indicators and Reagents | 1 | 1992 | 183 | 0.03 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.03 | Why? |
| Health Personnel | 2 | 2018 | 29646 | 0.03 | Why? |
| Nose | 1 | 1997 | 1093 | 0.03 | Why? |
| Administration, Inhalation | 1 | 1997 | 1647 | 0.03 | Why? |
| RNA, Viral | 4 | 2020 | 32276 | 0.03 | Why? |
| Animals | 4 | 2021 | 78931 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2017 | 1394 | 0.03 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.03 | Why? |
| Rhinitis | 1 | 1997 | 626 | 0.03 | Why? |
| Patient Positioning | 1 | 2021 | 1505 | 0.03 | Why? |
| Renal Insufficiency | 1 | 2017 | 810 | 0.03 | Why? |
| Viral Interference | 1 | 1989 | 33 | 0.03 | Why? |
| Biological Therapy | 1 | 2014 | 456 | 0.02 | Why? |
| Drug Discovery | 2 | 2014 | 3092 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.02 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2018 | 5002 | 0.02 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 2426 | 0.02 | Why? |
| China | 3 | 2020 | 50654 | 0.02 | Why? |
| Leukocyte Count | 1 | 1999 | 3178 | 0.02 | Why? |
| Recurrence | 1 | 1998 | 3675 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2017 | 1530 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.02 | Why? |
| Acute Disease | 2 | 1998 | 6029 | 0.02 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Vaccination | 1 | 2012 | 19050 | 0.02 | Why? |
| Biological Assay | 1 | 1989 | 367 | 0.02 | Why? |
| Interferon beta-1a | 1 | 1989 | 316 | 0.02 | Why? |
| Protease Inhibitors | 1 | 2021 | 3630 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| High-Throughput Screening Assays | 1 | 2013 | 1783 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.02 | Why? |
| Length of Stay | 1 | 2002 | 11042 | 0.02 | Why? |
| Smoking | 1 | 1997 | 3358 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Antifungal Agents | 1 | 2014 | 1828 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 1998 | 7220 | 0.02 | Why? |
| Antibodies, Viral | 2 | 2016 | 51949 | 0.02 | Why? |
| Acoustic Impedance Tests | 1 | 2002 | 16 | 0.02 | Why? |
| Nasopharynx | 2 | 2002 | 10224 | 0.02 | Why? |
| Eustachian Tube | 1 | 2002 | 20 | 0.02 | Why? |
| Neutralization Tests | 1 | 2016 | 6698 | 0.02 | Why? |
| Hypoxia | 1 | 2017 | 3626 | 0.01 | Why? |
| Aircraft | 1 | 2006 | 498 | 0.01 | Why? |
| Interferons | 1 | 2013 | 2885 | 0.01 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 7868 | 0.01 | Why? |
| Pressure | 1 | 2002 | 289 | 0.01 | Why? |
| Eosinophil Granule Proteins | 1 | 1999 | 6 | 0.01 | Why? |
| Epithelial Cells | 1 | 1992 | 3508 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 1989 | 3776 | 0.01 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.01 | Why? |
| Fomites | 1 | 2006 | 709 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Disease Transmission, Infectious | 2 | 2017 | 9044 | 0.01 | Why? |
| Recombinant Proteins | 1 | 1989 | 3786 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Ships | 1 | 2006 | 1046 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Vero Cells | 1 | 2013 | 14117 | 0.01 | Why? |
| Cell Line | 1 | 1992 | 12040 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Adenoviridae | 1 | 2002 | 1151 | 0.01 | Why? |
| Incidence | 1 | 1997 | 25622 | 0.01 | Why? |
| Receptors, Virus | 1 | 1992 | 5659 | 0.01 | Why? |
| Blood Proteins | 1 | 1999 | 551 | 0.01 | Why? |
| United States | 1 | 2021 | 46150 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2016 | 21571 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2002 | 88759 | 0.01 | Why? |
| Bacteria | 1 | 2002 | 1897 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Adenoviridae Infections | 1 | 1991 | 150 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2016 | 25288 | 0.01 | Why? |
| Virus Shedding | 1 | 2006 | 5834 | 0.01 | Why? |
| Paramyxoviridae Infections | 1 | 1991 | 364 | 0.01 | Why? |
| Herpes Simplex | 1 | 1991 | 272 | 0.01 | Why? |
| Inflammation Mediators | 1 | 1999 | 2654 | 0.01 | Why? |
| Travel | 1 | 2006 | 7220 | 0.01 | Why? |
| Enterovirus Infections | 1 | 1991 | 404 | 0.00 | Why? |
| Mass Screening | 1 | 2006 | 8005 | 0.00 | Why? |
| Morbidity | 1 | 1991 | 1426 | 0.00 | Why? |
| Students | 1 | 2002 | 5255 | 0.00 | Why? |
| Urban Population | 1 | 1991 | 2000 | 0.00 | Why? |
| Poverty | 1 | 1991 | 2302 | 0.00 | Why? |
| Quarantine | 1 | 2006 | 18418 | 0.00 | Why? |
| Emergency Service, Hospital | 1 | 1999 | 14232 | 0.00 | Why? |
| Brazil | 1 | 1991 | 12582 | 0.00 | Why? |
| Cross-Sectional Studies | 1 | 1999 | 53120 | 0.00 | Why? |
| Infant, Newborn | 1 | 1991 | 23105 | 0.00 | Why? |
| Prevalence | 1 | 1991 | 25773 | 0.00 | Why? |